1. Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR- ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial 
Houda Bahig, Ying Yuan, Abdallah S.R. Mohamed, Kristy K. Brock, Sweet Ping Ng, Jihong Wang, Yao Ding, Kate Hutcheson, Molly McCulloch, Peter A. Balter, Stephen Y. Lai, Abrahim Al-Mamgani, Jan-Jakob Sonke, Uulke A. van der Heide, Christopher Nutting, X. Allen Li, Jared Robbins, Mussadiq Awan, Irene Karam, Katherine Newbold, Kevin Harrington, Uwe Oelfke, Shreerang Bhide, Marielle E.P. Philippens, Chris H.J. Terhaard, Andrew J. McPartlin, Pierre Blanchard, Adam S. Garden, David I. Rosenthal, Gary B. Gunn, Jack Phan, Guillaume Cazoulat, Michalis Aristophanous, Kelli K. McSpadden, John A. Garcia, Cornelis A.T. van den Berg, Cornelis P.J. Raaijmakers, Linda Kerkmeijer, Patricia Doornaert, Sanne Blinde, Steven J. Frank, Clifton D. Fuller 
Clinical and Translational Radiation Oncology 
Volume 13, Pages (November 2018)
DOI: /j.ctro
Copyright © 2018 The Authors Terms and Conditions

2. Fig. 1
Scheme of the 2-stage trial design. ECOG = Eastern Cooperative Oncology Group; MRgRT = Magnetic-Resonance guided radiotherapy; IMRT = Intensity Modulated Radiotherapy.
Clinical and Translational Radiation Oncology  , 19-23DOI: ( /j.ctro )
Copyright © 2018 The Authors Terms and Conditions